Silencing of CD40 in vivo reduces progression of experimental atherogenesis through an NF-κB/miR-125b axis and reveals new potential mediators in the pathogenesis of atherosclerosis-Reference-Cited by-同舟云学术

Silencing of CD40 in vivo reduces progression of experimental atherogenesis through an NF-κB/miR-125b axis and reveals new potential mediators in the pathogenesis of atherosclerosis

Published:2016-12 Issue: Volume:255 Page:80-89
ISSN:0021-9150
Container-title:Atherosclerosis
language:en
Short-container-title:Atherosclerosis

Author:

Hueso Miguel^ORCID,De Ramon Laura,Navarro Estanislao,Ripoll Elia,Cruzado Josep M.,Grinyo Josep M.,Torras Joan

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference47 articles.

1. The immune system in atherosclerosis;Hansson;Nat. Immunol.,2011

2. The multi-functionality of CD40L and its receptor CD40 in atherosclerosis;Lievens;Thromb. Haemost.,2009

3. Molecular mechanism and function of CD40/CD40L engagement in the immune system;Elgueta;Immunol. Rev.,2009

4. Deficient CD40-TRAF6 signaling in leukocytes prevents atherosclerosis by skewing the immune response toward an antiinflammatory profile;Lutgens;J. Exp. Med.,2010

5. miRNAs in atherosclerotic plaque initiation, progression, and rupture;Andreou;Trends Mol. Med.,2015

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ticagrelor downregulates the expression of proatherogenic and proinflammatory miR125-b compared to clopidogrel: A randomized, controlled trial;International Journal of Cardiology;2024-07

2. microRNA-125b-1-3p mediates autophagy via the RRAGD/mTOR/ULK1 signaling pathway and mitigates atherosclerosis progression;Cellular Signalling;2024-06

3. Co-stimulators CD40-CD40L, a potential immune-therapy target for atherosclerosis: A review;Medicine;2024-04-05

4. Development of cationic solid lipid nanoparticles incorporating cholesteryl-9-carboxynonanoate (9CCN) for delivery of antagomiRs to macrophages;European Journal of Pharmaceutics and Biopharmaceutics;2024-04

5. In vivo inhibition of miR-125b modulates monocyte trafficking through the CCR7 receptor and attenuates atherosclerosis;2024-03-26